

TEL: 886-2-87923311 ext 10552  
FAX: 886-2-2793-6049 / 2792-9201  
E-mail: tsghirb@ndmctsgh.edu.tw



國防醫學院三軍總醫院  
人體試驗審議會  
人體試驗計畫同意函

11490 台北市內湖區成功路二段  
325 號 醫療大樓五樓 5113 室  
No. 325, Sec.2, Cheng-Kung Rd.  
Neihu 11490, Taipei, Taiwan, R.O.C

本審議會核准編號：098-05-292  
計畫名稱：國人大腸直腸癌 DNA 甲基化生物標記的確認及應用  
執行機構：國防醫學院  
計畫主持人：周雨青教授  
共同主持人：吳昌杰醫師；蕭正文醫師；胡哲銘醫師

業經本院 2019 年 1 月 14 日人體試驗審議會第一審議會審查通過持續審查報告，該計畫案經評估屬低度風險，(持續審查頻率為每年一次)，有效期限至 2020 年 3 月 18 日，特此證明。

本審議會的運作，遵循藥品優良臨床試驗準則及政府相關法律規章。計畫主持人應於同意函有效期屆滿前二個月，提出展延申請，本案須經本院人體試驗審議會通過後，方可繼續執行。

Letter of Approval  
Institutional Review Board, Tri-Service General Hospital

TSGHIRB No.: 098-05-292

Protocol title: The confirmation and application of colorectal cancer by DNA methylation markers

Research institution: National Defense Medical Center

Principle investigator: Yu-Ching Chou

Co-Investigator: Chang-Chieh Wu、Cheng-Wen Hsiao、Hu Je-Ming

On 01/14/2019, the Institutional Review Board I of the Tri-Service General Hospital approved the above-named application for the follow-up review. Assessed as Low Risk, the protocol is subject to follow-up review annually. The board is organized and operated in compliance with International Conference on Harmonization (ICH) / WHO Good Clinical Practice (GCP) and applicable laws and regulations. This approval is valid for 1 year till 03/18/2020. The principle investigator is required to submit the application for extension 2 months before the expiration date.



Institutional Review Board

余慕賢

Yu Ma Hsien

Chairman